Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS105 with dalpiciclib and fulvestrant in PIK3CA-mutated HR+/HER2- breast cancer
NCT07207070Phase 3Recruiting
- Sponsor
- Risen Pharma
- Start
- Nov 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JS105 in breast cancer, sponsored by Risen Pharma. Started Nov 2025; status: recruiting.
02
Drugs
JS105
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07207070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207070.